Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 13, 2025

Cyclin D1 Antibody

RRID:AB_2228523 Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 2922, RRID:AB_2228523)

Antibody Information

URL: http://antibodyregistry.org/AB_2228523

Proper Citation: (Cell Signaling Technology Cat# 2922, RRID:AB_2228523)

Target Antigen: Ccnd1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10695719, AB_2228523.

Antibody Name: Cyclin D1 Antibody

Description: This polyclonal targets Ccnd1

Target Organism: rat, mouse, human

Antibody ID: AB_2228523

Vendor: Cell Signaling Technology

Catalog Number: 2922

Record Creation Time: 20231110T045630+0000

Record Last Update: 20241115T112856+0000

Ratings and Alerts

No rating or validation information has been found for Cyclin D1 Antibody.

No alerts have been found for Cyclin D1 Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Jacob JR, et al. (2024) miRNA-194-3p represses NF-?B in gliomas to attenuate iPSC genes and proneural to mesenchymal transition. iScience, 27(1), 108650.

Lizardo MM, et al. (2024) Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis. Clinical cancer research: an official journal of the American Association for Cancer Research, 30(19), 4464.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. Cell reports, 43(5), 114134.

Dimitrov J, et al. (2024) Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. Frontiers in immunology, 15, 1470620.

Restaino AC, et al. (2024) Tumor-associated genetic amplifications impact extracellular vesicle miRNA cargo and their recruitment of nerves in head and neck cancer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 38(13), e23803.

Yip HYK, et al. (2024) Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. NPJ precision oncology, 8(1), 20.

Fu K, et al. (2024) Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell, 187(4), 882.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666.

Shanmugam S, et al. (2023) Ethanol inhibition of undifferentiated rat neural progenitor cell replication can be prevented by chlorogenic acid via the NFATc4/CSE signaling pathway. Alcohol, clinical & experimental research, 47(8), 1530.

Kombiyil S, et al. (2023) In Vitro Anti-cancer Effect of Crataegus oxyacantha Berry Extract on

Hormone Receptor Positive and Triple Negative Breast Cancers via Regulation of Canonical Wnt Signaling Pathway. Applied biochemistry and biotechnology, 195(4), 2687.

Flint AC, et al. (2023) Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. Clinical cancer research: an official journal of the American Association for Cancer Research, 29(17), 3438.

Yang Y, et al. (2023) ?KG-driven RNA polymerase II transcription of cyclin D1 licenses malic enzyme 2 to promote cell-cycle progression. Cell reports, 42(7), 112770.

Li X, et al. (2023) YAP regulates the liver size during the fasting-refeeding transition in mice. Acta pharmaceutica Sinica. B, 13(4), 1588.

Hao L, et al. (2021) Repurposing the anthelmintic praziquantel to treat psoriasis. British journal of pharmacology, 178(23), 4726.

Zhang Z, et al. (2021) Activation of metabotropic glutamate receptor 4 regulates proliferation and neural differentiation in neural stem/progenitor cells of the rat subventricular zone and increases phosphatase and tensin homolog protein expression. Journal of neurochemistry, 156(4), 465.

Yoo HC, et al. (2020) A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. Cell metabolism, 31(2), 267.

Maqbool SN, et al. (2020) Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC. British journal of pharmacology, 177(10), 2365.

Xiao B, et al. (2020) Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. Cell reports, 31(4), 107571.

Zhao R, et al. (2020) Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase. British journal of pharmacology, 177(10), 2303.

Liu Q, et al. (2020) T63 induces apoptosis in nasopharyngeal carcinoma cells through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway. Translational cancer research, 9(8), 4635.